We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+11.33%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$914M
AUM Growth
+$58.1M
(+6.8%)
Cap. Flow
-$16.6M
Cap. Flow
% of AUM
-1.81%
Top 10 Holdings %
Top 10 Hldgs %
41.85%
Holding
74
New
9
Increased
27
Reduced
22
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$33.6M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$25M |
| 3 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
+$14.7M |
| 4 |
XLRN
Acceleron Pharma
XLRN
|
+$13.9M |
| 5 |
Evolent Health
EVH
|
+$12.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SHPG
Shire pic
SHPG
|
+$30.3M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$29.7M |
| 3 |
Teladoc Health
TDOC
|
+$15M |
| 4 |
ALDR
Alder Biopharmaceuticals
ALDR
|
+$14.8M |
| 5 |
Intuitive Surgical
ISRG
|
+$10.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Pfizer
PFE
$143B
| $47.2M | 5.16% |
1,481,892
+270,454
| +22% | +$8.53M |
|
2
Johnson & Johnson
JNJ
$609B
| $46.8M | 5.12% |
354,048
+11,698
| +3% | +$1.49M |
|
3
Merck
MRK
$315B
| $46.8M | 5.11% |
764,498
+8,909
| +1% | +$542K |
|
4
Novartis
NVS
$293B
| $46.7M | 5.11% |
624,174
+97,092
| +18% | +$6.88M |
|
|
5
Medtronic
MDT
$106B
| $35.4M | 3.87% |
+398,360
| New | +$33.6M |
|
|
FOLD
6
DELISTED
Amicus Therapeutics
FOLD
| $35.1M | 3.84% |
3,483,990
-827,706
| -19% | -$6.66M |
|
|
ABMD
7
DELISTED
Abiomed Inc
ABMD
| $32.9M | 3.59% |
229,272
-32,419
| -12% | -$4.36M |
|
|
8
Regeneron Pharmaceuticals
REGN
$70.9B
| $30.9M | 3.38% |
62,898
+57,203
| +1,004% | +$25M |
|
9
Acadia Pharmaceuticals
ACAD
$4.38B
| $30.6M | 3.35% |
1,098,809
+427,696
| +64% | +$12.7M |
|
|
CELG
10
DELISTED
Celgene Corp
CELG
| $30.4M | 3.32% |
233,768
-38,298
| -14% | -$4.69M |
|
|
NUVA
11
DELISTED
NuVasive, Inc.
NUVA
| $30.3M | 3.31% |
393,289
+1,300
| +0.3% | +$97.2K |
|
12
Acadia Healthcare
ACHC
$3.17B
| $29.8M | 3.26% |
603,210
-87,800
| -13% | -$3.89M |
|
13
BioMarin Pharmaceuticals
BMRN
$11.5B
| $28.5M | 3.11% |
313,382
-1,851
| -0.6% | -$168K |
|
|
KTWO
14
DELISTED
K2M Group Holdings, Inc
KTWO
| $25M | 2.74% |
1,028,219
+191,699
| +23% | +$4.26M |
|
15
DexCom
DXCM
$29.6B
| $24.4M | 2.67% |
1,333,364
-96,000
| -7% | -$1.77M |
|
|
PTLA
16
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $23.7M | 2.59% |
422,143
-181,898
| -30% | -$7.29M |
|
17
Collegium Pharmaceutical
COLL
$1.17B
| $22.6M | 2.47% |
1,808,750
+529,503
| +41% | +$5.23M |
|
|
AERI
18
DELISTED
Aerie Pharmaceuticals
AERI
| $21.2M | 2.31% |
402,674
+13,251
| +3% | +$617K |
|
19
Teva Pharmaceuticals
TEVA
$37.3B
| $20M | 2.19% |
602,279
-151,542
| -20% | -$4.69M |
|
20
Viatris
VTRS
$20.1B
| $19.2M | 2.1% |
495,804
-114,939
| -19% | -$4.41M |
|
21
Edwards Lifesciences
EW
$49.4B
| $19M | 2.07% |
481,140
-120,297
| -20% | -$4.39M |
|
|
22
Teladoc Health
TDOC
$1.7B
| $18.8M | 2.06% |
543,073
-515,480
| -49% | -$15M |
|
|
XLRN
23
DELISTED
Acceleron Pharma
XLRN
| $18.4M | 2.01% |
604,499
+478,099
| +378% | +$13.9M |
|
|
LOXO
24
DELISTED
Loxo Oncology, Inc
LOXO
| $17.8M | 1.95% |
221,795
+131,405
| +145% | +$7.28M |
|
|
LJPC
25
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $17.6M | 1.92% |
589,959
+511,259
| +650% | +$14.7M |
|
Similar funds
RIP
CCM
LFWA
FWA
CF
WIM
MW
AFC
Sectoral Asset Management's Q2 2017 Portfolio in Review
As of Q2 2017, Sectoral Asset Management held 74 positions worth $914M, up 6.8% from $856M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Sectoral Asset Management's Q2 2017 filing shows 9 new, 27 increased, 22 reduced and 13 closed positions. Its largest new stake was Medtronic: 398,360 shares worth $35.4M. The largest sale was Shire pic, an estimated $30.3M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 94% a quarter earlier.
- Sectoral Asset Management's largest Q2 2017 buy was Medtronic: 398,360 shares worth $35.4M.
- Sectoral Asset Management added most to Regeneron Pharmaceuticals in Q2 2017, an estimated $25M increase.
- Sectoral Asset Management's biggest Q2 2017 reduction was Neurocrine Biosciences, cutting an estimated $29.7M.
- Sectoral Asset Management fully exited Shire pic in Q2 2017, selling an estimated $30.3M.
- Sectoral Asset Management's ten largest holdings make up 42% of its $914M portfolio in Q2 2017.
- Sectoral Asset Management opened 9 new positions and closed 13 in Q2 2017.
- Sectoral Asset Management's portfolio value rose 6.8% quarter-over-quarter to $914M.
Based on Sectoral Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.